REFRACTORY MULTIPLE MYELOMA

This study tested the drug trametinib in 35 adults with advanced cancers that have specific BRAF genetic changes (non-V600 mutations or fusions). The goal was to see if trametinib could shrink or stop cancer growth by blocking certain proteins. While the treatment may help contro…

This study is for people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an NF2 mutation. The drug defactinib works by blocking a protein (FAK) that helps these cancer cells grow. Researchers want to see if the drug can shrink tumo…

This study tests a drug called copanlisib in 35 adults with advanced or treatment-resistant cancers that have a specific change in the PTEN gene. The drug blocks a protein that helps cancer cells grow, aiming to shrink tumors or stop them from spreading. The main goal is to see h…

This study tests the drug crizotinib in people whose advanced or treatment-resistant solid tumors, lymphoma, or multiple myeloma have a specific genetic change called MET amplification. Crizotinib works by blocking signals that help cancer cells grow and spread. The main goal is …

This study tests a combination of four drugs (daratumumab, clarithromycin, pomalidomide, and dexamethasone) in people with multiple myeloma whose cancer returned or did not respond after prior treatment with daratumumab. The goal is to see if this combo can shrink tumors more eff…

This study tests a drug called afatinib in 19 adults with advanced cancers (like lymphoma or solid tumors) that have a specific EGFR gene mutation and have stopped responding to standard treatments. Afatinib works by blocking the faulty EGFR protein that helps cancer cells grow. …

This study tests a drug called trametinib in 50 adults with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. Par…

This study tests a daily pill called osimertinib in people with advanced cancers that have certain EGFR gene changes. The drug blocks a faulty protein that helps tumors grow. Researchers want to see if it can shrink tumors or slow the disease in 19 patients with various cancer ty…

This study tests a drug called binimetinib in 53 adults with advanced cancers that have a specific genetic change (NRAS mutation). The drug blocks proteins that help cancer grow. Researchers want to see if it can shrink tumors or stop them from growing. This is a phase II trial f…

This study tests a drug called erdafitinib in people with advanced cancers that have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. The goal is to see if it can shrink tumors or stop them from getting worse for at least 6 months. About 35 …

This study tested the drug crizotinib in 4 people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called ROS1 translocation. The drug blocks a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors or st…

This study tests a drug called GSK2636771 in 35 adults with advanced cancers that have lost a protein called PTEN. The drug blocks a growth signal that these cancer cells rely on. Researchers want to see if it can shrink tumors or stop them from growing. This is a phase II trial,…

This study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…

This study tests a drug called MLN0128 (TAK-228) in people with advanced cancers that have specific genetic changes (TSC1 or TSC2 mutations). The drug works by blocking enzymes that cancer cells need to grow. About 49 participants will receive the treatment to see if it can shrin…

This study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. Sunitinib works by blocking signals that tell cancer cells to grow. The goal is to see if the drug can shrink or slow the cancer. About 10 adults with certain lymphom…

This study tests a drug called larotrectinib in people with advanced cancers that have a specific genetic change called an NTRK fusion. The drug blocks a faulty protein that helps cancer cells grow. About 35 adults with various solid tumors or lymphomas that haven't responded to …

This study tests a drug called AZD1775 in people whose advanced cancers have a BRCA gene mutation. The drug blocks a protein that cancer cells need to grow. The goal is to see if the drug can shrink tumors or stop them from growing. About 35 adults with various advanced cancers a…

This study tests a new combination of drugs for people with multiple myeloma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see if the combination can shrink or control the cancer. About 39 adults will take part, receiving ei…

This study tests a combination of four drugs (selinexor, bortezomib, dexamethasone, and daratumumab) in 62 adults with multiple myeloma that has returned or not responded to prior treatments. The goal is to see how many patients achieve a significant reduction in cancer. Because …

This study tests a drug called crizotinib in people with advanced cancers that have a specific genetic change called MET exon 14 deletion. The drug blocks enzymes that help cancer cells grow and spread. About 20 participants will receive the treatment to see if their tumors shrin…

This study tests a drug called MLN0128 (TAK-228) in 35 adults with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an mTOR mutation. The drug works by blocking enzymes that cancer cells need to grow. The goal is to see if the drug can s…

This study tests a combination of four drugs (isatuximab, carfilzomib, pomalidomide, and dexamethasone) in 30 adults whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see how many patients' tumors shrink or disappear. This is not a cure…

This study tests a drug called GSK2636771 in people with advanced cancers that have a specific genetic change (PTEN mutation or deletion). The drug blocks a protein that may help these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from grow…

This early-phase study was designed to test the safety and best dose of an experimental oral drug called GB1211 (selvigaltin) when added to standard therapy for multiple myeloma that has returned or stopped responding. The drug targets a protein linked to inflammation and cancer …

This study tests a drug called ulixertinib in people with advanced cancers that have certain changes in the BRAF gene (mutations or fusions). The drug works by blocking signals that tell cancer cells to grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that h…

This study tests a drug called taselisib in people whose cancer has a specific genetic change (PIK3CA mutation) but not certain other changes. The drug aims to block a protein that helps cancer grow. About 70 adults with advanced solid tumors or lymphomas that haven't responded t…

This study tests two targeted drugs, dabrafenib and trametinib, in people with advanced cancers that have a specific BRAF gene mutation (V600E or V600K). The goal is to see if the combination can shrink tumors or stop them from growing. About 44 adults with various cancer types (…

This study tests the drug trametinib in people with advanced cancers that have GNAQ or GNA11 gene mutations. Trametinib blocks certain proteins that help these cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from getting worse. Only 4 patients too…

This study tests a drug called ipatasertib in 35 people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an AKT mutation. The drug works by blocking a protein that helps cancer cells grow. The main goal is to see if the tumors shrin…

This study tested a drug called crizotinib in people with advanced cancers that have a specific genetic change called ALK rearrangement. The goal was to see if the drug could shrink tumors or stop them from growing. Only 5 patients took part, and the results help researchers unde…

This early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to prior therapies. It combines specially engineered natural killer (NK) cells (called TiNK) with an antibody drug (isatuximab) and standard chemotherapy. The main goal is to…

This study tested whether taking lenalidomide (a drug that helps the immune system fight cancer) after a stem cell transplant could delay the return of multiple myeloma. About 460 patients with active myeloma received either lenalidomide or a placebo after their transplant. The g…

This study tests a drug called afatinib in 40 patients whose advanced cancers have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer cells from growing. The goal is to see if the drug can shrink tumors or slo…

This study tests a drug called ado-trastuzumab emtansine in people with advanced cancers that have too many HER2 receptors (HER2 amplification), except breast and stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Rese…

This early-phase trial tests a combination of three drugs (elotuzumab, mezigdomide, and dexamethasone) in 12 adults with multiple myeloma that has come back or stopped responding after prior treatments. The goal is to find a safe dose and see if the combination can control the ca…

This study tests a drug called copanlisib in people whose advanced cancers have a specific genetic change (PIK3CA mutation). The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with var…

This study tested a drug called AZD5363 in 35 people with advanced cancers that have a specific genetic change (AKT mutation). The drug works by blocking a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing. This is…

This early-phase trial tests a personalized cell therapy (CAR T) that targets a protein called BCMA on myeloma cells. It is for people whose multiple myeloma has returned or not responded to at least three prior treatments. The main goal is to check safety and find the right dose…

This study tests a drug called vismodegib in people with advanced or treatment-resistant cancers (solid tumors, lymphoma, or multiple myeloma) that have specific changes in the SMO or PTCH1 genes. The drug blocks a protein that helps cancer grow. The goal is to see if the drug ca…

This study looks at how doctors in Italy currently treat a type of blood cancer called multiple myeloma when it stops responding to three main drug classes. Researchers will collect information from medical records of about 250 patients to understand which treatments are used and…

This study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…

This pilot study explores whether using a lab test that screens many drugs at once, combined with genetic information, can help choose personalized treatments for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to therapy. The goal is …